Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

British Journal of Haematology

Volumn 164, Issue 6, 2014, Pages 811-821

  Gandhi, Anita K ^a   Kang, Jian ^a   Havens, Courtney G ^a   Conklin, Thomas ^a   Ning, Yuhong ^a   Wu, Lei ^a   Ito, Takumi ^b   Ando, Hideki ^b   Waldman, Michelle F ^a   Thakurta, Anjan ^a   Klippel, Anke ^a   Handa, Hiroshi ^b   Daniel, Thomas O ^a   Schafer, Peter H ^a   Chopra, Rajesh ^a  

^a CELGENE CORPORATION   (United States)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Aiolos; Cereblon; Ikaros; Lenalidomide; Pomalidomide

Indexed keywords

AIOLOS TRANSCRIPTION FACTOR; BINDING PROTEIN; CEREBLON; IKAROS TRANSCRIPTION FACTOR; INTERLEUKIN 2; LENALIDOMIDE; POMALIDOMIDE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME REGULATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOMODULATION; MOLECULAR MODEL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; UBIQUITINATION; VOLUNTEER;

AIOLOS; CEREBLON; IKAROS; LENALIDOMIDE; POMALIDOMIDE;

ANGIOGENESIS INHIBITORS; HUMANS; IKAROS TRANSCRIPTION FACTOR; IMMUNOLOGIC FACTORS; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; T-LYMPHOCYTES; THALIDOMIDE; TRANSCRIPTION FACTORS; TRANSFECTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84894754079     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12708     Document Type: Article

References (30)

1. Bandyopadhyay, S., Duré, M., Paroder, M., Soto-Nieves, N., Puga, I. & Macián, F. (2007) Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood, 109, 2878-2886.
2. Billot, K., Parizot, C., Arrouss, I., Mazier, D., Debre, P., Rogner, U.C. & Rebollo, A. (2010) Differential Aiolos expression in human hematopoietic subpopulations. Leukemia Research, 34, 289-293.
3. Cai, Q., Dierich, A., Oulad-Abdelghani, M., Chan, S. & Kastner, P. (2009) Helios deficiency has minimal impact on T cell development and function. Journal of Immunology, 183, 2303-2311.
4. Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J.B., Knight, R. & Laskin, O.L. (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Journal of Clinical Pharmacology, 47, 1466-1475.
5. Corral, L.G., Haslett, P.A., Muller, G.W., Chen, R., Wong, L.M., Ocampo, C.J., Patterson, R.T., Stirling, D.I. & Kaplan, G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. Journal of Immunology, 163, 380-386.
6. Dredge, K., Marriott, J.B., Todryk, S.M., Muller, G.W., Chen, R., Stirling, D.I. & Dalgleish, A.G. (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Thl-type immunity. Journal of Immunology, 168, 4914-4919.
7. Ferreirós-Vidal, I., Carroll, T., Taylor, B., Terry, A., Liang, Z., Bruno, L., Dharmalingam, G., Khadayate, S., Cobb, B.S., Smale, S.T., Spivakov, M., Srivastava, P., Petretto, E., Fisher, A.G. & Merkenschlager, M. (2013) Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood, 121, 1769-1782.
8. Galustian, C., Meyer, B., Labarthe, M.C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., Schafer, P., Bartlett, J.B. & Dalgleish, A.G. (2008) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology Immunotherapy, 58, 1033-1045.
9. Gandhi, R., Kumar, D., Burns, E.J., Nadeau, M., Dake, B., Laroni, A., Kozoriz, D., Weiner, H.L. & Quintana, F.J. (2010) Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nature Immunology, 11, 846-853.
10. Gandhi, A.K., Shi, T., Li, M., Jungnelius, U., Romano, A., Tabernero, J., Siena, S., Schafer, P.H. & Chopra, R. Immunomodulatory. (2013) Effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. PLoS ONE, 8, e80437.
11. Iacobucci, I., Lonetti, A., Messa, F., Cilloni, D., Arruga, F., Ottaviani, E., Paolini, S., Papayannidis, C., Piccaluga, P.P., Giannoulia, P., Soverini, S., Amabile, M., Poerio, A., Saglio, G., Pane, F., Berton, G., Baruzzi, A., Vitale, A., Chiaretti, S., Perini, G., Foà, R., Baccarani, M. & Martinelli, G. (2008) Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood, 112, 3847-3855.
12. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. & Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity. Science, 327, 1345-1350.
13. Kim, J., Sif, S., Jones, B., Jackson, A., Koipally, J., Heller, E., Winandy, S., Viel, A., Sawyer, A., Ikeda, T. & Kingst, R. (1999) Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity, 10, 345-355.
14. Kim, W., Bennett, E.J., Huttlin, E.L., Guo, A., Li, J., Possemato, A., Sowa, M.E., Rad, R., Rush, J., Comb, M.J., Harper, J.W. & Gygi, S.P. (2011) Systematic and quantitative assessment of the ubiquitin modified proteome. Molecular Cell, 44, 325-340.
15. Koipally, J., Renold, A., Kim, J. & Georgopoulos, K. (1999) Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO Journal, 18, 3090-3100.
16. Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., Mahmoudi, A., Cathers, B., Rychak, E., Gaidarova, S., Chen, R., Schafer, P.H., Handa, H., Daniel, T.O., Evans, J.F. & Chopra, R. (2012) Cereblon is a direct target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26, 2326-2335.
17. Ma, S., Pathak, S., Mandal, M., Trinh, L., Clark, M.R. & Lu, R. (2010) Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Molecular and Cellular Biology, 30, 4149-4158.
18. Nückel, H., Frey, U.H., Sellmann, L., Collins, C.H., Dührsen, U. & Siffert, W. (2008) The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia. British Journal of Haematology, 144, 268-270.
19. H17 differentiation by directly silencing Il2 expression. Nature Immunology, 13, 770-778.
20. Ramsay, A.G., Johnson, A.J., Lee, A.M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J.C. & Gribben, J.G. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation, 118, 2427-2437.
21. Schafer, P.H., Gandhi, A.K., Loveland, M.A., Chen, R.S., Man, H.W., Schnetkamp, P.P., Wolbring, G., Govinda, S., Corral, L.G., Payvandi, F., Muller, G.W. & Stirling, D.I. (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. Journal of Pharmacology and Experimental Therapeutics, 305, 1222-1232.
22. Smyth, G.K. (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology, 3, article 3.
23. Sun, L., Goodman, P.A., Wood, C.M., Crotty, M.L., Sensel, M., Sather, H., Navara, C., Nachman, J., Steinherz, P.G., Gaynon, P.S., Seibel, N., Vassilev, A., Juran, B.D., Reaman, G.H. & Uckun, F.M. (1999) Expression of aberrantly spliced oncogenic Ikaros isoforms in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 17, 3753-3766.
24. Thomas, R.M., Chunder, N., Chen, C., Umetsu, S.E., Winandy, S. & Wells, A.D. (2007) Ikaros enforces the costimulatory requirement for IL-2 gene expression and is required for anergy induction in CD4+ T lymphocytes. Journal of Immunology, 179, 7305-7315.
25. Thompson, E.C., Cobb, B.S., Sabbattini, P., Meixlsperger, S., Parelho, V., Liberg, D., Taylor, B., Dillon, N., Georgopoulos, K., Jumaa, H., Smale, S.T., Fisher, A.G. & Merkenschlager, M. (2007) Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity, 26, 335-344.
26. Wang, J.H., Nichogiannopoulou, A., Wu, L., Sun, L., Sharpe, A.H., Bigby, M. & Georgopoulos, K. (1996) Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity, 5, 537-549.
27. Wang, J.H., Avitahl, N., Cariappa, A., Friedrich, C., Ikeda, T., Renold, A., Andrikopoulos, K., Liang, L., Pillai, S., Morgan, B.A. & Georgopoulos, K. (1998) Aiolos regulates B cell activation and maturation to effector state. Immunity, 9, 543-553.
28. Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P. & Bartlett, J.B. (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clinical Cancer Research, 14, 4650-4657.
29. Yang, L., Luo, Y. & Wei, J. (2010) Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncology Reports, 24, 571-577.
30. Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771-4779.